Lenzilumab and azacitidine in proliferative CMML: insights from the PREACH-M study
143 بار بازدید -
7 ماه پیش
-
Daniel Thomas, MD, PhD, South
Daniel Thomas, MD, PhD, South Australian Health and Medical Research Institute, Adelaide, Australia, presents early findings from the PREcision Approach to CHronic Myelomonocytic Leukemia (PREACH-M; ACTRN12621000223831) trial, in which patients with chronic myelomonocytic leukemia (CMML) in the proliferative phase are treated with a combination of lenzilumab and azacitidine. Preliminary results are encouraging, with a complete response (CR) or marrow CR and a reduction in blast count observed in 79% of patients. Dr Thomas highlights the therapeutic potential of immunotherapy in CMML as it is an inflammatory disease in which high levels of inflammatory cytokines have been identified in patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
7 ماه پیش
در تاریخ 1402/11/10 منتشر شده
است.
143
بـار بازدید شده